ロード中...
EXTH-03. TRIPTOLIDE, A NOVEL THERAPEUTIC AGENT FOR IDH1-MUTATED GLIOMA
BACKGROUND: Isocitrate dehydrogenase (IDH1/2) mutations are common genetic abnormalities in human malignancies, which result in neomorphic enzyme activity that catalyzes 2-hydroxyglutarate (2-HG) production. While IDH mutations are recognized as critical cancer-associated genetic changes, the therap...
保存先:
| 出版年: | Neuro Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6847942/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.337 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|